Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
| ▸ | CCR4 | P51679 | 11/20 | 0.33 |
| ▸ | ERN1 | O75460 | 2/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | S100A9 | P06702 | 2/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30429927 | 0.72 | PRKDC (0.34) | PRKDCERN1KDM4EALDH1A1TSHR | |
| SCHEMBL29951175 | 0.71 | ERN1 (0.46) | PRKDCERN1SRCKDM4EALDH1A1 | |
| SCHEMBL30498408 | 0.71 | CA1 (0.37) | PRKDCERN1SRCKDM4EALDH1A1 | |
| SCHEMBL28216990 | 0.71 | CCR1 (0.41) | PRKDCERN1KDM4EALDH1A1TSHR | |
| SCHEMBL25342803 | 0.71 | ERN1 (0.41) | PRKDCCCR4ERN1ALDH1A1S100A9 | |
| SCHEMBL29587853 | 0.71 | CCR1 (0.41) | PRKDCERN1KDM4EALDH1A1TSHR | |
| SCHEMBL8580981 | 0.71 | ALDH1A1 (0.49) | CCR4ERN1SRCKDM4EALDH1A1 | |
| SCHEMBL671095 | 0.71 | ERN1 (0.46) | PRKDCERN1EGFRERBB2KDM4E | |
| SCHEMBL5784164 | 0.71 | ERN1 (0.46) | PRKDCERN1SRCKDM4EALDH1A1 | |
| SCHEMBL25758165 | 0.71 | CA1 (0.37) | PRKDCERN1SRCKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101019-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP1) INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2025-03-27 | — | — | US | disclosed |
| EP-4469456-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP1) INHIBITORS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2024-12-04 | — | — | EP | disclosed |
| CN-118871439-A | Inhibitors of ectonucleotide pyrophosphatase-phosphodiesterase (ENPP 1) and uses thereof | 英矽智能科技知识产权有限公司 | 2024-10-29 | — | — | CN | disclosed |
| WO-2023143520-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP1) INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101019-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, ENPP2 | PRKDC 542/4885CCR4 4841/4885ERN1 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.